Nanobi­otix shares rock­et up on a mar­gin­al suc­cess for soft tis­sue sar­co­ma; As­traZeneca wins pi­o­neer­ing PD-L1 OK in In­dia

→ Shares of Nanobi­otix (Eu­ronext: NANO) soared af­ter the biotech re­port­ed pos­i­tive though mar­gin­al re­sults for its Phase II/III study of NBTXR3 in soft tis­sue sar­co­ma. But the key out­come was not great. Nanobi­otix re­port­ed that “twice as many pa­tients (16.1% vs 7.9%) achieved a patho­log­i­cal Com­plete Re­sponse (pCR) with NBTXR3 com­pared to the con­trol arm (p = 0.0448).” That’s bare­ly a pass­ing grade, but in­vestors seemed to like it. The p-val­ue on the sec­ondary was an equal­ly unim­pres­sive 0.042. Its shares rock­et­ed up 50% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER